Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas

Wang, P, Dong, Q, Zhang, C, Kuan, P-F, Liu, Y, Jeck, W R, Andersen, J B, Jiang, W +18 more·2013·Oncogene
DOI 10.1038/onc.2012.315

Cited by (398)

Items 101–200 of 398

  1. <i>IDH</i> Mutation Subgroup Status Associates with Intratumor Heterogeneity and the Tumor Microenvironment in Intrahepatic Cholangiocarcinoma
    Xiang, Xiao, Liu, Ziyang, Zhang, Chong, Li, Zhao, Gao, Jie, Zhang, Changkun, Cao, Qi, Cheng, Jinghui, Liu, Hengkang, Chen, Dingbao et al. · 2021 · Advanced Science
  2. IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas
    Arjen H.G. Cleven, Johnny Suijker, Georgios Agrogiannis, Inge H. Briaire‐de Bruijn, Norma Frizzell, Attje S. Hoekstra, Pauline M. Wijers‐Koster, Anne‐Marie Cleton-Jansen, Judith V.M.G. Bovée · 2017 · Clinical Sarcoma Research
  3. Intrahepatic cholangiocarcinoma: current management and emerging therapies
    Amir Ata Rahnemai‐Azar, Allison B. Weisbrod, Mary E. Dillhoff, Carl Richard Schmidt, Timothy Michael Pawlik · 2017 · Expert Review of Gastroenterology & Hepatology
  4. A cfDNA methylation-based tissue-of-origin classifier for cancers of unknown primary
    Alicia‐Marie Conway, Simon P. Pearce, Alexandra Clipson, Steven M. Hill, Francesca Chemi, Daniel Slane-Tan, Saba Ferdous, Arman Hossain, Katarzyna Kamieniecka, Daniel J. White et al. · 2024 · Nature Communications
  5. Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas
    Yukinari Kato · 2014 · Brain Tumor Pathology
  6. Isocitrate dehydrogenase variants in cancer — Cellular consequences and therapeutic opportunities
    Shuang Liu, Tom A.D. Cadoux-Hudson, Christopher John Schofield · 2020 · Current Opinion in Chemical Biology
  7. Mitogen-Activated Protein Kinases (MAPKs) and Cholangiocarcinoma: The Missing Link
    Chaobo Chen, Leonard J. Nelson, Matias Antonio Avila, Francisco Javier Cubero · 2019 · Cells
  8. Molecular pathogenesis of intrahepatic cholangiocarcinoma
    Jesper Bøje Andersen · 2014 · Journal of Hepato-Biliary-Pancreatic Sciences
  9. Global DNA methylation and hydroxymethylation differ in hepatocellular carcinoma and cholangiocarcinoma and relate to survival rate
    Silvia Udali, Patrizia Guarini, Sara Moruzzi, Andrea Ruzzenente, Stephanie A. Tammen, Alfredo Guglielmi, Simone Conci, Patrizia Pattini, Oliviero Olivieri, Roberto Corrocher et al. · 2015 · Hepatology
  10. Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications
    Daniel H. Ahn, Tanios Bekaii‐Saab · 2017 · Journal of Gastrointestinal Oncology
  11. IDH Mutations in Tumorigenesis and Their Potential Role As Novel Therapeutic Targets
    Daniel Krell, Paul James Mulholland, Adam Enver Frampton, Jonathan Krell, Justin Stebbing, Chiara Bardella · 2013 · Future Oncology
  12. Cell-free DNA from bile outperformed plasma as a potential alternative to tissue biopsy in biliary tract cancer
    Qing Gou, C.Z. Zhang, Zhanguo Sun, Lei Wu, Y. Chen, Zhanjie Mo, Qicong Mai, Jian He, Zhigang Zhou, F. Shi et al. · 2021 · ESMO Open
  13. Cholangiocarcinoma: risk factors, environmental influences and oncogenesis.
    Redha Al-Bahrani, Yasser Abuetabh, Nikolas Zeitouni, Consolato Maria Sergi · 2013 · PubMed
  14. New developments in systemic therapy for advanced biliary tract cancer
    Chigusa Morizane, Makoto Ueno, Masafumi Ikeda, Takuji Okusaka, Hiroshi Ishii, Junji Furuse · 2018 · Japanese Journal of Clinical Oncology
  15. SLC1A1-mediated cellular and mitochondrial influx of R-2-hydroxyglutarate in vascular endothelial cells promotes tumor angiogenesis in IDH1-mutant solid tumors
    Xiaomin Wang, Ziqi Chen, Jun Xu, Shuai Tang, Nan An, Lei Jiang, Yixiang Zhang, Shaoying Zhang, Qingli Zhang, Yanyan Shen et al. · 2022 · Cell Research
  16. The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer
    Hwajeong Lee, Jeffrey S. Ross · 2017 · Therapeutic Advances in Gastroenterology
  17. Genetics of Opisthorchis viverrini-related cholangiocarcinoma
    Apinya Jusakul, Sarinya Kongpetch, Bin Tean Teh · 2015 · Current Opinion in Gastroenterology
  18. Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype
    Elisabet Cuyàs, Salvador Fernández‐Arroyo, Bruna Corominas-Faja, Esther Rodríguez‐Gallego, Joaquim Bosch‐Barrera, Begoña Martı́n-Castillo, Rafel Llorens, Jorge Joven, Javier Abel Menéndez · 2015 · Oncotarget
  19. Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and α-KG
    Anna Catharina Navis, Simone P. Niclou, Fred Fack, Daniel Stieber, Sanne A. M. van Lith, Kiek N. Verrijp, Alan J. Wright, Jonathan Stauber, Bastiaan B.J. Tops, Irene Otte‐Höller et al. · 2013 · Acta Neuropathologica Communications
  20. High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers
    Matteo Fassan, Michele Simbolo, Emilio Bria, Andrea Mafficini, Sara Pilotto, Paola Capelli, Maria Bencivenga, Sara Pecori, Claudio Luchini, Diogo Neves et al. · 2013 · Gastric Cancer
  21. Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma
    Mitesh J. Borad, Gregory James Gores, Lewis Rowland Roberts · 2015 · Current Opinion in Gastroenterology
  22. 5-Hydroxymethylcytosine Profiling as an Indicator of Cellular State
    Alexander Laird, John P. Thomson, David James Harrison, Richard R. Meehan · 2013 · Epigenomics
  23. Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression
    Alphonse Eugene Sirica, Mario Strazzabosco, Massimiliano Cadamuro · 2020 · Advances in cancer research
  24. Systemic treatment of advanced or recurrent biliary tract cancer
    Wei Zhang, Hongyuan Zhou, Yingying Wang, Zewu Zhang, Guangtai Cao, Tianqiang Song, Ti Zhang, Qiang Li · 2020 · BioScience Trends
  25. Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations
    Ingvild Comfort Hvinden, Tom A.D. Cadoux-Hudson, Christopher John Schofield, James McCullagh · 2021 · Cell Reports Medicine
  26. Mutant IDH in Gliomas: Role in Cancer and Treatment Options
    Georgios Solomou, Alina Finch, Asim Asghar, Chiara Bardella · 2023 · Cancers
  27. Molecular docking and molecular dynamics studies reveal structural basis of inhibition and selectivity of inhibitors EGCG and OSU-03012 toward glucose regulated protein-78 (GRP78) overexpressed in glioblastoma
    Rituparna Bhattacharjee, Arpita Devi, Seema Mishra · 2015 · Journal of Molecular Modeling
  28. D-2-hydroxyglutarate is essential for maintaining oncogenic property of mutant IDH-containing cancer cells but dispensable for cell growth
    Shenghong Ma, Bowen Jiang, Wanglong Deng, Zhong-Kai Gu, Fei-Zhen Wu, Tingting Li, Yukun Xia, Hui Yang, Dan Ye, Yue Xiong et al. · 2015 · Oncotarget
  29. Maffucci syndrome and neoplasms: a case report and review of the literature
    Olga Prokopchuk, Stephanie Andres, Karen Becker, Konstantin Holzapfel, Daniel Hartmann, Helmut Frieß · 2016 · BMC Research Notes
  30. Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma
    Alexandra R. Grassian, Raymond A. Pagliarini, Derek Y. Chiang · 2014 · Current Opinion in Gastroenterology
  31. The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine
    Lorenza Rimassa, Nicola Personeni, Alessio Aghemo, Ana Lleò · 2019 · Journal of Autoimmunity
  32. Driver mutations of intrahepatic cholangiocarcinoma shape clinically relevant genomic clusters with distinct molecular features and therapeutic vulnerabilities
    Xiangyu Wang, Wenwei Zhu, Zheng Wang, Jian-Bo Huang, Shenghao Wang, Fumao Bai, Tian‐En Li, Ying Zhu, Jing Zhao, Xin Yang et al. · 2021 · Theranostics
  33. IDH1, a CHOP and C/EBPβ-responsive gene under ER stress, sensitizes human melanoma cells to hypoxia-induced apoptosis
    Xuejun Yang, Tongde Du, Xiang Wang, Yingqiu Zhang, Wanglai Hu, Xiaofeng Du, Lin Miao, Chuanchun Han · 2015 · Cancer Letters
  34. Proximity ligation assay evaluates IDH1R132H presentation in gliomas
    Lukas Bunse, Theresa Schumacher, Felix Sahm, Stefan Pusch, Iris Oezen, Katharina J. Rauschenbach, Marina Gonzalez, Gergely Morten Solecki, Matthias Osswald, David Capper et al. · 2015 · Journal of Clinical Investigation
  35. TET enzymatic oxidation of 5-methylcytosine, 5-hydroxymethylcytosine and 5-formylcytosine
    Jean Cadet, J. Richard Wagner · 2013 · Mutation Research/Genetic Toxicology and Environmental Mutagenesis
  36. Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers
    Ramona Bledea, Varshini Vasudevaraja, Seema V. Patel, James M. Stafford, Jonathan Serrano, Gianna Esposito, Lilian M. Tredwin, Nina E. Goodman, Andreas Kloetgen, John G. Golfinos et al. · 2019 · Scientific Reports
  37. Next-Generation Biomarkers for Cholangiocarcinoma
    Pedro Miguel Rodrigues, Arndt Vogel, Marco A. Arrese, Domingo Cesar Balderramo, Juan W. Valle, Jesús M. Bañales · 2021 · Cancers
  38. Epigenome Remodeling in Cholangiocarcinoma
    Colm J. O’Rourke, Juan F. Lafuente-Barquero, Jesper Bøje Andersen · 2019 · Trends in cancer
  39. Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing
    Juan Putra, Francine Blumental De Abreu, Jason D. Peterson, J. Marc Pipas, Kabir Mody, Christopher Ian Amos, Gregory J. Tsongalis, Arief Antonius Suriawinata · 2015 · Experimental and Molecular Pathology
  40. Epigenome dysregulation in cholangiocarcinoma
    Colm J. O’Rourke, Patricia Muñoz-Garrido, Esmeralda L. Aguayo, Jesper Bøje Andersen · 2017 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
  41. Intrahepatic cholangiocarcinoma: can imaging phenotypes predict survival and tumor genetics?
    Emily Alanna Aherne, Linda M. Pak, Debra A. Goldman, Mithat Gönen, William R. Jarnagin, Amber L. Simpson, Richard K. Do · 2018 · Abdominal Radiology
  42. Cholangiocarcinoma 2020: the next horizon in mechanisms and management
    Banales, Jesus M., Marin, Jose J. G., Lamarca, Angela, Rodrigues, Pedro M., Khan, Shahid A., Roberts, Lewis R., Cardinale, Vincenzo, Carpino, Guido, Andersen, Jesper B., Braconi, Chiara et al. · 2020 · Nature Reviews Gastroenterology &amp; Hepatology
  43. Novel targeted treatment options for advanced cholangiocarcinoma
    Amit Mahipal, Anuhya Kommalapati, Sri Harsha Tella, Alexander Lim, Richard D. Kim · 2018 · Expert Opinion on Investigational Drugs
  44. The Emerging Role of D-2-Hydroxyglutarate as an Oncometabolite in Hematolymphoid and Central Nervous System Neoplasms
    Dinesh Rakheja, Leonard Jeffrey Medeiros, Scott Bevan, Weina Chen · 2013 · Frontiers in Oncology
  45. Pathogenesis of cholangiocarcinoma: From genetics to signalling pathways
    Sarinya Kongpetch, Apinya Jusakul, Choon Kiat Ong, Weng Khong Lim, Steve Rozen, Patrick B. O. Tan, Bin Tean Teh · 2015 · Best Practice & Research Clinical Gastroenterology
  46. Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic Strategies
    Hanumantha Rao Madala, Surendra Reddy Punganuru, Viswanath Arutla, Subhasis Misra, Thresia Thomas, Kalkunte S. Srivenugopal · 2018 · Cancers
  47. The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo
    Johnny Suijker, Hans J. Baelde, Helene Roelofs, Anne‐Marie Cleton-Jansen, Judith V.M.G. Bovée · 2015 · Oncotarget
  48. Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options
    Nicola Personeni, Ana Lleò, Tiziana Pressiani, Francesca Colapietro, Mark Robert Openshaw, Chara Stavraka, Athanasios Pouptsis, David James Pinato, Lorenza Rimassa · 2020 · Cancers
  49. Molecular characteristics of biliary tract cancer
    Davendra P. S. Sohal, Shiva Shrotriya, Mohamed E. Abazeed, Michael W. Cruise, Alok A. Khorana · 2016 · Critical Reviews in Oncology/Hematology
  50. Otto Warburg: The journey towards the seminal discovery of tumor cell bioenergetic reprogramming
    Ana M. Urbano · 2020 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
  51. IDH mutations in liver cell plasticity and biliary cancer
    Supriya K. Saha, Christine A. Parachoniak, Nabeel M. Bardeesy · 2014 · Cell Cycle
  52. Current biologics for treatment of biliary tract cancers
    Diana Yi Zhao, Kian‐Huat Lim · 2017 · Journal of Gastrointestinal Oncology
  53. Reporting Tumor Molecular Heterogeneity in Histopathological Diagnosis
    Andrea Mafficini, Eliana Amato, Matteo Fassan, Michele Simbolo, Davide Antonello, Caterina Vicentini, Maria Scardoni, Samantha Bersani, Marisa Gottardi, Borislav Chavdarov Rusev et al. · 2014 · PLoS ONE
  54. Primary acute myeloid leukemia cells with IDH1 or IDH2 mutations respond to a DOT1L inhibitor in vitro
    Shawn M. Sarkaria, Matthew J Christopher, Jeffery M. Klco, Timothy James Ley · 2014 · Leukemia
  55. L2hgdh Deficiency Accumulates l -2-Hydroxyglutarate with Progressive Leukoencephalopathy and Neurodegeneration
    Shenghong Ma, Renqiang Sun, Bowen Jiang, Jun Gao, Wanglong Deng, Peng Liu, Ruoyu He, Jing Cui, Minbiao Ji, Wei Yi et al. · 2017 · Molecular and Cellular Biology
  56. Molecular Targets in Cholangiocarcinoma
    Colm J. O’Rourke, Patricia Muñoz-Garrido, Jesper Bøje Andersen · 2020 · Hepatology
  57. Molecular Pathogenesis of Cholangiocarcinoma
    Sumera H. Rizvi, Gregory James Gores · 2014 · Digestive Diseases
  58. IDH1, lipid metabolism and cancer: Shedding new light on old ideas
    Elena Bogdanovic · 2015 · Biochimica et Biophysica Acta (BBA) - General Subjects
  59. Quality and performance of validated prognostic models for survival after resection of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis
    Stefan Buettner, Boris Galjart, Berend R. Beumer, Jeroen L.A. van Vugt, Casper H.J. van Eijck, Wojciech Grzegorz Polak, Jeroen de Jonge, Marjolein Y.V. Homs, Lydi M.J.W. van Driel, Timothy Michael Pawlik et al. · 2020 · HPB
  60. Emerging molecular targets and therapy for cholangiocarcinoma
    Hamzeh Kayhanian, Elizabeth Catherine Smyth, Chiara Braconi · 2017 · World Journal of Gastrointestinal Oncology
  61. PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
    Angela Dalia Ricci, Alessandro Rizzo, Chiara Bonucci, Nastassja Tober, Andrea Palloni, Veronica Mollica, Ilaria Maggio, Marzia Deserti, Simona Tavolari, Giovanni Brandi · 2020 · Medicines
  62. Future directions in the treatment of cholangiocarcinoma
    Andrew Xiuxuan Zhu · 2015 · Best Practice & Research Clinical Gastroenterology
  63. Clinicopathological, radiologic, and molecular study of 23 combined hepatocellular-cholangiocarcinomas with stem cell features, cholangiolocellular type
    Jun Chen, Jian He, Min Deng, Hongyan Wu, Jiong Shi, Liang Mao, Qi Sun, Min Tang, Xiangshan Fan, Yudong Qiu et al. · 2017 · Human Pathology
  64. Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase–mutated intrahepatic cholangiocarcinomas
    J Delahousse, Loïc Verlingue, Sophie Broutin, Clémence Legoupil, Mehdi Touat, Ludovic S. Doucet, Samy Ammari, Ludovic Lacroix, Michel Pierre Ducreux, Jean‐Yves Scoazec et al. · 2018 · European Journal of Cancer
  65. Therapy for advanced cholangiocarcinoma: Current knowledge and future potential
    Mingxun Wang, Ziyan Chen, Pengyi Guo, Yi Wang, Gang Chen · 2020 · Journal of Cellular and Molecular Medicine
  66. Clinical Efficacy of Olaparib in IDH1/IDH2- Mutant Mesenchymal Sarcomas
    Joseph P. Eder, Deborah B. Doroshow, Khanh T Do, Vicki Leigh Keedy, Jeffrey Sklar, Peter M. Glazer, Ranjit S. Bindra, Geoffrey Ira Shapiro · 2021 · JCO Precision Oncology
  67. Epigenetic reduction of DNA repair in progression to gastrointestinal cancer
    Carol Bernstein · 2015 · World Journal of Gastrointestinal Oncology
  68. Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy
    Marianeve Carotenuto, Alessandra Sacco, Laura Forgione, Nicola Normanno · 2022 · Exploration of Targeted Anti-tumor Therapy
  69. IDH1‐mutant cancer cells are sensitive to cisplatin and an IDH1‐mutant inhibitor counteracts this sensitivity
    Mohammed Khurshed, Niels Aarnoudse, Renske Hulsbos, Vashendriya V.V. Hira, Hanneke W.M. van Laarhoven, Johanna W. Wilmink, Remco Jurriaan Molenaar, Cornelis J.F. Van Noorden · 2018 · The FASEB Journal
  70. Role of 5-hydroxymethylcytosine level in diagnosis and prognosis prediction of intrahepatic cholangiocarcinoma
    Zhao‐Ru Dong, Chi Zhang, Jiabin Cai, Pengfei Zhang, Guo‐Ming Shi, Dongmei Gao, Hui‐Chuan Sun, Shuang–Jian Qiu, Jian Zhou, Ai‐Wu Ke et al. · 2014 · Tumor Biology
  71. Genetic profiling of intrahepatic cholangiocarcinoma and its clinical implication in targeted therapy.
    Diyang Xie, Zhenggang Ren, Jia Fan, Qiang Gao · 2016 · PubMed Central
  72. Is the IDH Mutation a Good Target for Chondrosarcoma Treatment?
    Elena Cojocaru, Christopher P. Wilding, Bodil Engelman, Paul H. Huang, Robin L. Jones · 2020 · Current Molecular Biology Reports
  73. Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors
    Satish K. Chitneni, Zachary J. Reitman, Rebecca Spicehandler, David M. Gooden, Hai Yan, Michael R. Zalutsky · 2018 · Bioorganic & Medicinal Chemistry Letters
  74. Therapeutic Potential of Autophagy Modulation in Cholangiocarcinoma
    Héctor Perez‐Montoyo · 2020 · Cells
  75. Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?
    Loïc Verlingue, Antoine Hollebecque, Valérie Boige, Michel Pierre Ducreux, David Malka, Charles Ferté · 2017 · European Journal of Cancer
  76. Emerging role of precision medicine in biliary tract cancers
    James M. Bogenberger, Thomas DeLeon, Mansi Arora, Daniel H. Ahn, Mitesh J. Borad · 2018 · npj Precision Oncology
  77. Valproic Acid Enhanced Temozolomide-Induced Anticancer Activity in Human Glioma Through the p53–PUMA Apoptosis Pathway
    Hong‐Chieh Tsai, Kuo‐Chen Wei, Pin‐Yuan Chen, Chiung-Yin Huang, Ko‐Ting Chen, Ya-Jui Lin, Hsiao-Wei Cheng, Yi-Rou Chen, Hsiang‐Tsui Wang · 2021 · Frontiers in Oncology
  78. Innovative Medicine
    Kazuwa Nakao, Nagahiro Minato, Shinji Üemoto · 2015 · Springer eBooks
  79. Update on cholangiocarcinoma: potential impact of genomic studies on clinical management
    Dirk H. Walter, Sylvia Hartmann, Oliver Waidmann · 2017 · Zeitschrift für Gastroenterologie
  80. Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation
    Avani Athauda, Caroline Fong, David K. Lau, Milind M. Javle, Ghassan K. Abou‐Alfa, Chigusa Morizane, Keith Steward, Ian Chau · 2020 · Cancer Treatment Reviews
  81. IDH1 Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment—Current State and Future Perspectives
    Fabiana Crispo, Michele Pietrafesa, Valentina Condelli, Francesca Maddalena, Giuseppina Bruno, Annamaria Piscazzi, Alessandro Sgambato, Franca Esposito, Matteo Landriscina · 2020 · Molecules
  82. Ten‐Eleven Translocation 1 Promotes Malignant Progression of Cholangiocarcinoma With Wild‐Type Isocitrate Dehydrogenase 1
    Xuewei Bai, Hongyu Zhang, Yamei Zhou, Katsuya Nagaoka, Jialin Meng, Chengcheng Ji, Dan Liu, Xianghui Dong, Kevin Y. Cao, Joud Mulla et al. · 2020 · Hepatology
  83. Targeting Isocitrate Dehydrogenase (IDH) in Solid Tumors: Current Evidence and Future Perspectives
    Francesca Carosi, Elisabetta Broseghini, Laura Fabbri, Giacomo Corradi, Riccardo Gili, Valentina Forte, Roberta Roncarati, Daria Maria Filippini, Manuela Ferracin · 2024 · Cancers
  84. IDH1 R132C mutation is detected in clear cell hepatocellular carcinoma by pyrosequencing
    Jung Hee Lee, Dong‐Hoon Shin, Won Young Park, Nari Shin, Ahrong Kim, Hyun Jung Lee, Young Keum Kim, Kyung Un Choi, Jee Yeon Kim, Young Il Yang et al. · 2017 · World Journal of Surgical Oncology
  85. Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?
    Chiara Braconi, Stephanie K. Roessler, Beata Kruk, Frank Lammert, Marcin Jan Krawczyk, Jesper Bøje Andersen · 2019 · Liver International
  86. R-2HG downregulates ERα to inhibit cholangiocarcinoma via the FTO/m6A-methylated ERα/miR16-5p/YAP1 signal pathway
    Yuan Gao, Xiwu Ouyang, Li Zuo, Yao Xiao, Yin Sun, Chawnshang Chang, Xihu Qin, Shuyuan Yeh · 2021 · Molecular Therapy — Oncolytics
  87. Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study
    Mario Domenico Rizzato, Stefano Brignola, Giada Munari, Maura Gatti, Vincenzo Dadduzio, Chiara Borga, Francesca Bergamo, Antonio Pellino, Valentina Angerilli, Claudia Mescoli et al. · 2022 · European Journal of Cancer
  88. Epidemiology, biology, and management of venous thromboembolism in gliomas: An interdisciplinary review
    Jasmin Jo, María Díaz, Craig Horbinski, Nigel Mackman, Stephen Joseph Bagley, Marika Broekman, Janusz W. Rak, James Perry, Ingrid Pabinger, Nigel S. Key et al. · 2023 · Neuro-Oncology
  89. DNA methylation-based classifier differentiates intrahepatic pancreato-biliary tumours
    Mihnea Paul Dragomir, Teodor G. Calina, Eilís Pérez, Simon Schallenberg, Meng Chen, Thomas Albrecht, Ines Koch, Peggy Wolkenstein, Benjamin Frank Goeppert, Stephanie K. Roessler et al. · 2023 · EBioMedicine
  90. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
    Gabriella Aitcheson, A. Mahipal, Binu V. John · 2021 · Expert Opinion on Investigational Drugs
  91. Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies
    Trang H. Au, Kai Wang, David Dean Stenehjem, Ignacio Garrido‐Laguna · 2017 · Journal of Gastrointestinal Oncology
  92. Sirtuin activation targets IDH-mutant tumors
    Julie J. Miller, Alexandria L. Fink, Jack A Banagis, Hiroaki Nagashima, Megha P. Subramanian, Christine Kyuyoung Lee, Lisa Melamed, Shilpa S. Tummala, Kensuke Tateishi, Hiroaki Wakimoto et al. · 2020 · Neuro-Oncology
  93. DNA direct reversal repair and alkylating agent drug resistance
    Roberto Gutierrez, Timothy R O'Connor · 2021 · Cancer Drug Resistance
  94. Molecular diagnosis of intrahepatic cholangiocarcinoma
    Hiroaki Haga, Tushar C. Patel · 2014 · Journal of Hepato-Biliary-Pancreatic Sciences
  95. Isocitrate dehydrogenase gene variants in cancer and their clinical significance
    Thomas A.D. Cadoux-Hudson, Christopher John Schofield, James McCullagh · 2021 · Biochemical Society Transactions
  96. Adjuvant Therapy for Intrahepatic Cholangiocarcinoma: The Debate Continues
    Andrew Xiuxuan Zhu, Jennifer Jane Knox · 2012 · The Oncologist
  97. Tissue 2-Hydroxyglutarate as a Biomarker for Isocitrate Dehydrogenase Mutations in Gliomas
    Hao‐Wen Sim, Romina Nejad, Wenjiang Zhang, Farshad Nassiri, Warren P. Mason, Kenneth Aldape, Gelareh Mohammed Zadeh, Eric Xueyu Chen · 2019 · Clinical Cancer Research
  98. Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets
    Douglas V.N.P. Oliveira, Shanshan Zhang, Xin Chen, Diego Francesco Calvisi, Jesper Bøje Andersen · 2017 · Expert Review of Gastroenterology & Hepatology
  99. Treatment with olaparib monotherapy for BRCA2-mutated refractory intrahepatic cholangiocarcinoma: a case report
    Yuan Cheng, Juan Zhang, Shukui Qin, Hai qing Hua · 2018 · OncoTargets and Therapy
  100. Epigenetic Regulatory Enzymes: mutation Prevalence and Coexistence in Cancers
    Amit Sharma, Hongde Liu, Martina C. Herwig‐Carl, Tikam Chand Dakal, Ingo G.H. Schmidt‐Wolf · 2021 · Cancer Investigation